The clinical potential of GDF15 as a "ready-to-feed indicator" for critically ill adults

Lisa Van Dyck, Jan Gunst, Michaël P Casaer, Bram Peeters, Inge Derese, Pieter J Wouters, Francis de Zegher, Ilse Vanhorebeek, Greet Van den Berghe, Lisa Van Dyck, Jan Gunst, Michaël P Casaer, Bram Peeters, Inge Derese, Pieter J Wouters, Francis de Zegher, Ilse Vanhorebeek, Greet Van den Berghe

Abstract

Background: Circulating growth-differentiation factor-15 (GDF15), a cellular stress marker, abruptly increases during critical illness, but its later time course remains unclear. GDF15 physiologically controls oral intake by driving aversive responses to nutrition. Early parenteral nutrition (PN) in ICU patients has overall been shown not beneficial. We hypothesized that low GDF15 can identify patients who benefit from early PN, tolerate enteral nutrition (EN), and resume spontaneous oral intake.

Methods: In secondary analyses of the EPaNIC-RCT on timing of PN initiation (early PN versus late PN) and the prospective observational DAS study, we documented the time course of circulating GDF15 in ICU (N = 1128) and 1 week post-ICU (N = 72), compared with healthy subjects (N = 65), and the impact hereon of randomization to early PN versus late PN in propensity score-matched groups (N = 564/group). Interaction between upon-admission GDF15 and randomization for its outcome effects was investigated (N = 4393). Finally, association between GDF15 and EN tolerance in ICU (N = 1383) and oral intake beyond ICU discharge (N = 72) was studied.

Results: GDF15 was elevated throughout ICU stay, similarly in early PN and late PN patients, and remained high beyond ICU discharge (p < 0.0001). Upon-admission GDF15 did not interact with randomization to early PN versus late PN for its outcome effects, but higher GDF15 independently related to worse outcomes (p ≤ 0.002). Lower GDF15 was only weakly related to gastrointestinal tolerance (p < 0.0001) and a steeper drop in GDF15 with more oral intake after ICU discharge (p = 0.05).

Conclusion: In critically ill patients, high GDF15 reflected poor prognosis and may contribute to aversive responses to nutrition. However, the potential of GDF15 as "ready-to-feed indicator" appears limited.

Trial registration: ClinicalTrials.gov , NCT00512122, registered 31 July 2007, https://www.clinicaltrials.gov/ct2/show/NCT00512122 (EPaNIC trial) and ISRCTN, ISRCTN 98806770, registered 11 November 2014, http://www.isrctn.com/ISRCTN98806770 (DAS trial).

Keywords: Critical illness; Feeding intolerance; GDF15; Outcome; Parenteral nutrition.

Conflict of interest statement

None of the authors has any conflict of interest to report.

Figures

Fig. 1
Fig. 1
Patient selection. Studied samples are depicted in gray. Randomization group refers to early PN versus late PN. GDF15, growth-differentiation factor-15; ICU, intensive care unit
Fig. 2
Fig. 2
Time course of GDF15 during critical illness. Serum concentrations of GDF15 were quantified in 65 healthy controls and in 564 early PN and 564 late PN ICU patients, who were matched for upon ICU admission characteristics, on the admission day, on day 4 or the last day in ICU for patients with a shorter ICU stay (d4/LD), on day 7 for patients still in ICU on that day, and on the last ICU day (left panels). In addition, in a smaller subset of patients with an ICU stay of at least 4 days, serum GDF15 concentrations were also quantified on day 1, day 2, and day 3 in the ICU (right panels). Numbers below each graph indicate, for each time point, how many patients had sufficient serum available for GDF15 measurement and were included in the analyses. P values, adjusted for multiple comparisons, for each time point are shown at the top of the graphs. Geometric shapes represent medians, and whiskers represent interquartile ranges. a Comparison of all patients with 65 control subjects (gray area representing interquartile ranges) who had never been admitted to an ICU. b Comparison of patients randomized to early PN versus late PN. c Comparison of ICU survivors and non-survivors
Fig. 3
Fig. 3
Relation of GDF15 with oral intake after ICU discharge. Plasma concentrations of GDF15 were quantified in 72 ICU patients on the last day in ICU and 7 days after ICU discharge. Macronutrient intake was scored semi-quantitatively based on estimated nutrient intake (low, moderate, and high intake meaning respectively  60% of a normal intake). Geometric shapes represent means, and error bars represent standard errors of the mean. Numbers in the figure legend indicate the number of patients per group. Data are shown on a logarithmic scale

References

    1. Van Dyck L, Casaer MP, Gunst J. Autophagy and its implications against early full nutrition support in critical illness. Nutr Clin Pract. 2018;33(3):339–347. doi: 10.1002/ncp.10084.
    1. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48–79. doi: 10.1016/j.clnu.2018.08.037.
    1. Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28(3):353–368. doi: 10.1016/j.cmet.2018.07.018.
    1. Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178(5):1231–1244. doi: 10.1016/j.cell.2019.07.033.
    1. Clark BJ, Bull TM, Benson AB, Stream AR, Macht M, Gaydos J, et al. Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study. Crit Care. 2013;17(3):R92. doi: 10.1186/cc12737.
    1. Dieplinger B, Egger M, Leitner I, Firlinger F, Poelz W, Lenz K, et al. Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients. J Crit Care. 2016;34:38–45. doi: 10.1016/j.jcrc.2016.03.020.
    1. Buendgens L, Yagmur E, Bruensing J, Herbers U, Baeck C, Trautwein C, et al. Growth differentiation factor-15 is a predictor of mortality in critically ill patients with sepsis. Dis Markers. 2017;2017:5271203. doi: 10.1155/2017/5271203.
    1. Hongisto M, Kataja A, Tarvasmaki T, Holopainen A, Javanainen T, Jurkko R, et al. Levels of growth differentiation factor 15 and early mortality risk stratification in cardiogenic shock. J Card Fail. 2019;25(11):894–901. doi: 10.1016/j.cardfail.2019.07.003.
    1. Patel S, Alvarez-Guaita A, Melvin A, Rimmington D, Dattilo A, Miedzybrodzka EL, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 2019;29(3):707–718. doi: 10.1016/j.cmet.2018.12.016.
    1. Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23(10):1150–1157. doi: 10.1038/nm.4392.
    1. Borner T, Shaulson ED, Ghidewon MY, Barnett AB, Horn CC, Doyle RP, et al. GDF15 induces anorexia through nausea and emesis. Cell Metab. 2020;31(2):351–362. doi: 10.1016/j.cmet.2019.12.004.
    1. Mullican SE, Rangwala SM. Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond. Trends Endocrinol Metab. 2018;29(8):560–570. doi: 10.1016/j.tem.2018.05.002.
    1. Peterson SJ, Tsai AA, Scala CM, Sowa DC, Sheean PM, Braunschweig CL. Adequacy of oral intake in critically ill patients 1 week after extubation. J Am Diet Assoc. 2010;110(3):427–433. doi: 10.1016/j.jada.2009.11.020.
    1. Heyland D, Cook DJ, Winder B, Brylowski L, Van deMark H, Guyatt G. Enteral nutrition in the critically ill patient: a prospective survey. Crit Care Med 1995;23(6):1055–1060.
    1. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365(6):506–517. doi: 10.1056/NEJMoa1102662.
    1. Casaer MP, Hermans G, Wilmer A, Van den Berghe G. Impact of early parenteral nutrition completing enteral nutrition in adult critically ill patients (EPaNIC trial): a study protocol and statistical analysis plan for a randomized controlled trial. Trials. 2011;12:21. doi: 10.1186/1745-6215-12-21.
    1. Peeters B, Meersseman P, Vander Perre S, Wouters PJ, Vanmarcke D, Debaveye Y, et al. Adrenocortical function during prolonged critical illness and beyond: a prospective observational study. Intensive Care Med. 2018;44(10):1720–1729. doi: 10.1007/s00134-018-5366-7.
    1. Van Dyck L, Derese I, Vander Perre S, Wouters PJ, Casaer MP, Hermans G, et al. The growth hormone axis in relation to accepting an early macronutrient deficit and outcome of critically ill patients. J Clin Endocrinol Metab. 2019;104(11):5507-18.
    1. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22(4):415–421. doi: 10.1016/S0261-5614(03)00098-0.
    1. Hermans G, Casaer MP, Clerckx B, Güiza F, Vanhullebusch T, Derde S, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med. 2013;1(8):621–629. doi: 10.1016/S2213-2600(13)70183-8.
    1. Dostalova I, Kavalkova P, Papezova H, Domluvilova D, Zikan V, Haluzik M, et al. Nutr Metab (Lond) 2010;7:34. doi: 10.1186/1743-7075-7-34.
    1. Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, Haluzikova D, et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol. 2009;161(3):397–404. doi: 10.1530/EJE-09-0417.
    1. Thiessen SE, Van den Berghe G, Vanhorebeek I. Mitochondrial and endoplasmic reticulum dysfunction and related defense mechanisms in critical illness-induced multiple organ failure. Biochim Biophys Acta Mol Basis Dis. 2017;1863(10 Pt B):2534–2545. doi: 10.1016/j.bbadis.2017.02.015.
    1. Thiessen SE, Vanhorebeek I, Derese I, Gunst J, Van den Berghe G. FGF21 response to critical illness: effect of blood glucose control and relation with cellular stress and survival. J Clin Endocrinol Metab. 2015;100(10):E1319–E1327. doi: 10.1210/jc.2015-2700.
    1. Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015;78(5):814–823. doi: 10.1002/ana.24506.
    1. Singer P, Hiesmayr M, Biolo G, Felbinger TW, Berger MM, Goeters C, et al. Pragmatic approach to nutrition in the ICU: expert opinion regarding which calorie protein target. Clin Nutr. 2014;33(2):246–251. doi: 10.1016/j.clnu.2013.12.004.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi